Table 2.

Summary of the clinical metadata of the ReMIND data collection.

Clinical Data (N=114)
Demographics		Histopathology
Age	47.50 [32.75 – 59.00]	Gliomas, glioneuronal, and neuronal tumors	83.3% (95/114)
Sex		Astrocytoma	34.7% (33/95)
Male	53.5% (61/114)	Glioblastoma	32.6% (31/95)
Female	46.5% (53/114)	Oligodendroglioma	25.3% (24/95)
Race		Other	7.4% (7/95)
White	90.4% (103/114)	Meningiomas	0.9% (1/114)
Asian	5.3% (6/114)	Hematolymphoid tumors	0.9% (1/114)
Declined	2.6% (3/114)	Metastases	9.6% (11/114)
Other	1.8% (2/114)	Other	5.3% (6/114)
Ethnicity
Not Hispanic	94.7% (108/114)	Adult-type diffuse gliomas (n=88)
Hispanic	4.4% (5/114)
Declined	0.9% (1/114)	WHO grade
		1	3.2% (3/88)
Preoperative MRI		2	31.6% (31/88)
Tesla		3	24.2% (23/88)
3T	71.1% (81/114)	4	38.9% (37/88)
1.5T	21.1% (24/114)	Not assigned	2.1% (2/88)
7T	1.8% (2/114)
1.16T	1.8% (2/114)	Molecular genetics
Eloquent		IDH (n=88)
Yes	67.5% (77/114)	IDH-mutant	64.8% (57/88)
No	32.5% (37/114)	IDH-wildtype	35.8% (31/88)
Enhancement	57.9% (66/114)	1p/19q (n=75)
T2/FLAIR hyperintensity	64.0% (73/114)	retained	65.3% (49/75)
Volume (cm3)	17.83 [6.31 –35.87]	co-deleted	33.3% (25/75)
Tumor depth		1p-retained, 19q-deleted	1.3% (1/75)
Gyral and subgyral	49.1% (56/114)	MGMT promoter (n=83)	94.3% (83/88)
Subgyral	33.3% (38/114)	Methylated	56.6 % (47/83)
Gyral	17.5% (20/114)	Unmethylated	34.9% (29/83)
		Partially methylated	8.4% (7/83)
Surgical parameters
Previous craniotomy
No	55.3% (63/114)
Yes	44.7% (51/114)
Anesthesia technique
General anesthesia	95.6% (109/114)
Awake craniotomy	4.4% (5/114)
Laterality
Left	50.0% (57/114)
Right	50.0% (57/114)
Resection after iMRI	71.1% (81/114)
Complete ultrasounds	80.7% (92/114)